CHICAGO — In patients with inflammatory bowel disease, a “strong and consistent three-way interaction” was identified between HLA-B27, male sex and the development of sacroiliitis, according to data presented at Digestive Disease Week.Sacroiliitis occurs in approximately 20% of patients with IBD, often aligned with male sex and HLA-B27 status; however, large-scale studies on the
Target levels of infliximab in patients with IBD and high visceral adipose fat burden may be higher, suggesting the potential need to personalize dosing strategies.
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).
There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.